MAP2K1 and astrocytoma (excluding glioblastoma): In one such study, it was reported that basal IL‐6 levels were higher in astrocytoma xenografts with resistance to selumetinib (a MEK1/MEK2 inhibitor) than in parental selumetinib‐sensitive astrocytoma xenografts (Bid et al., 2013).